Neuropsychiatric symptoms are common in Parkinson's disease (PD) and have a disproportionate impact on quality of life and carer burden. Pharmacological treatment is the main approach in dealing with these symptoms, but it is limited by variable efficacy and risk of drug interactions. Non-pharmacological approaches using the cognitive-behavioural therapy (CBT) model are viable alternatives and in this review paper we summarise the evidence of CBT for three of the most common psychiatric manifestations of PD: depression and anxiety, impulse-control disorders and insomnia. Most studies modified the usual CBT format to include modules accounting for problems specific to PD: activity scheduling around motoric function, motor symptoms as triggers of anxiety, fear of falling and preparation for disease progression as well as accommodation of materials for suspected executive dysfunction. We found a growing evidence base that CBT (modified to account for PD-specific problems) is effective in the treatment of PD psychiatric symptoms. Where controlled study design was used, moderate effect sizes are reported for the efficacy of CBT for depression, including with distance administration of CBT. The effects were sustained during follow-up which was between 1 and 6 months. In addition, there are some initial data on the effects of CBT on impulse-control disorders and insomnia. The studies were limited by their small and potentially unrepresentative samples and the quality of sample reporting (eg, concomitant antidepressant and dopaminergic therapy use). Additional welldesigned and adequately powered studies are required to determine the utility of CBT in PD.
INTRODUCTIONParkinson's disease (PD) is classically defined by a triad of motor symptoms (tremor, rigidity and bradykinesia). It is, however, increasingly conceptualised as a neuropsychiatric disorder 1 in view of the high prevalence of psychiatric features, including depression, impulse control disorders (ICD) and sleep difficulties.2 These non-motor complications are better predictors of disability, distress and rates to institutionalisation than the motor symptoms.3 Of the non-motor complications, mixed depression and anxiety is the most common psychiatric comorbidity, affecting ∼50% of PD patients, significantly more common that rates in the general population.4 Depression and anxiety are the strongest predictors of poorer quality of life, 5 even in the advanced stages of the illness where the motor features have progressed fully.6 ICD are characterised by repetitive, reward-based behaviours, linked to the dopaminergic medication used to treat the motor symptoms. They affect ∼14% of all PD patients 7 and are associated with psychiatric comorbidity and high carer burden.8 Sleep disturbance is another neuropsychiatric symptom that affects up to 60% of all PD patients.9 It is associated with somnolence 10 and impairment in attention and executive function.11 On the basis of their impact on quality of life and outcome, the recognition and treatment of neuropsych...